Proton therapy is associated with fewer in-field second cancers in retinoblastoma survivors
At 15 years, in-field second malignancy incidence was 0% after proton RT versus 11.1% after photons in 108 retinoblastoma patients.
At 15 years, in-field second malignancy incidence was 0% after proton RT versus 11.1% after photons in 108 retinoblastoma patients.
Two patients developed reversible unilateral cortical enhancement and neurological deficits four and nine years after cranial RT, mimicking tumor recurrence.
Automated cardiac contouring was considered acceptable with at most minor corrections for 93.8% of 630 structures, although coronary arteries remained challenging.
Practical pelvic contouring guidance illustrates how cervical involvement, extensive LVSI and bladder motion influence postoperative endometrial cancer target volumes.
In 36 previously irradiated head and neck cancer patients, CyberKnife SBRT achieved 55% one-year local control; smoking exposure predicted worse outcomes.
PET-detected nodal upstaging was associated with >10% PTV expansion in 48% versus 17% of patients, accompanied by increased lung exposure.
GEC-ESTRO supports interstitial brachytherapy boost for selected high-risk breast cancer patients, emphasizing dose escalation with reduced surrounding tissue exposure.
Two patients with tumor-induced acute pancreatitis experienced pain relief and declining pancreatic enzymes after palliative radiotherapy of 8 Gy/2 or 20 Gy/5.
ProSpare reduced anorectal dose and showed lower grade ≥1 bowel toxicity at 18 weeks, while the trial's primary two-year endpoint remains pending.
Five studies worth your time this week, spanning randomized evidence, long-term toxicity, salvage treatment, surveillance and particle-therapy QA.
Adding solid-water extensions restored PTV gamma agreement to 98–100% at 1%/1 mm, whereas unextended wide-field calibration performed poorly.
New ESTRO-EPTN recommendations define validated, risk-based pathways for introducing independent dose calculation and machine log-file QA in scanned particle therapy.
A nonclinical time-driven PBS configuration delivered 25 Gy in approximately 0.6 seconds at 42 Gy/s while preserving proton range and scanning accuracy.
Whole-bladder MR-guided online adaptation achieved acceptable CTV coverage in 94% of assessed fractions using 5-mm initial margins with selective expansion.
After 16.5 years, left atrial maximum dose was associated with major cardiac events, while left ventricular mean dose tracked with coronary disease.